Cooling off: Hyperthermic intraperitoneal chemotherapy is not associated with improved progression-free survival or overall survival in women with stage IV epithelial ovarian cancer

被引：0
|
作者：
Chau, Danielle [1 ]
Chambers, Laura [2 ]
Lampert, Erika [1 ]
Yao, Meng [1 ]
Morton, Molly [2 ]
Rose, Peter [1 ]
Michener, Chad [1 ]
Vargas, Roberto [1 ]
Debernardo, Robert [1 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH USA
[2] Ohio State Univ, Columbus, OH USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.140
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1230
引用
收藏
页码：S147 / S148
页数：2
相关论文
共 50 条
  • [1] The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma
    Gerestein, C. G.
    Eijkemans, M. J. C.
    de Jong, D.
    van der Burg, M. E. L.
    Dykgraaf, R. H. M.
    Kooi, G. S.
    Baalbergen, A.
    Burger, C. W.
    Ansink, A. C.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2009, 116 (03) : 372 - 380
  • [2] Cisplatin and paclitaxel are associated with improved progression-free survival compared to cisplatin alone during interval debulking surgery with hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian cancer
    Chambers, Laura
    Horowitz, Max
    Costales, Anthony
    Yao, Meng
    Chichura, Anna
    Morton, Molly
    Gruner, Morgan
    Rose, Peter
    Michener, Chad
    Debernardo, Robert
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S58 - S59
  • [3] DIFFERENCES IN CORRELATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL BY CLINICAL VARIABLES IN EPITHELIAL OVARIAN CANCER
    Paik, E. S.
    Jeong, S. Y.
    Kim, M. S.
    Kim, J. H.
    Kim, T. J.
    Lee, J. W.
    Kim, B. G.
    Bae, D. S.
    Choi, C. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 717 - 717
  • [4] DIFFERENCES IN CORRELATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL BY CLINICAL VARIABLES IN EPITHELIAL OVARIAN CANCER
    Paik, E. S.
    Kang, M.
    Lee, J. H.
    Kang, J. H.
    Jeong, S. Y.
    Kim, M. S.
    Lee, Y-Y
    Kim, T-J
    Lee, J-W
    Kim, B-G
    Bae, D-S
    Seo, J.
    Choi, C. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A504 - A505
  • [5] Effect of chemotherapy delays and dose reductions on progression-free and overall survival in the treatment of epithelial ovarian cancer
    Nagel, C.
    Backes, F.
    Donner, J.
    Hade, E.
    Copeland, L.
    Fowler, J.
    Cohn, D.
    O'Malley, D.
    Eisenhauer, E.
    Salani, R.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S123 - S123
  • [6] Extension of recurrence-free and overall survival in patients with ovarian cancer stage III using hyperthermic intraperitoneal chemotherapy (HIPEC)
    Grabenbauer, Gerhard G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (07) : 695 - 696
  • [7] Progression-free survival and overall survival in patients diagnosed with stage III/IV ovarian cancer and treated with primary surgery or neoadjuvant chemotherapy with or without delayed debulking surgery
    Russell, M.
    Twigg, J.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S101 - S101
  • [8] GPR30 expression predicts chemotherapy responsiveness and overall and progression-free survival in patients with epithelial ovarian cancer
    Smith, H. O.
    Arias-Pulido, H.
    Qualls, C. R.
    Lee, S.
    Kuo, D. Y.
    Verschraegen, C. F.
    Howard, T.
    Joste, N. E.
    Prossnitz, E. R.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S133 - S134
  • [9] Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
    Susana Banerjee
    Stan Kaye
    Current Oncology Reports, 2012, 14 : 483 - 485
  • [10] Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
    Banerjee, Susana
    Kaye, Stan
    CURRENT ONCOLOGY REPORTS, 2012, 14 (06) : 483 - 485
12345